PMID-18356831 – Tesofensine Weight Loss in Parkinsons and Alzheimers
Bhatti JK, et al. Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease. Obesity (Silver Spring). 2008;16(6):1363-1369.
Quick Reference
| Property | Value |
|---|---|
| PMID | 18356831 |
| DOI | 10.1038/oby.2008.55 |
| Year | 2008 |
| Journal | Obesity |
| Study Type | Observational (secondary analysis of RCT data) |
| Evidence Level | III |
| Sample | Patients with Parkinson's disease and Alzheimer's disease |
| Peptide(s) Studied | Tesofensine |
Key Findings
- Tesofensine was originally studied for neurodegenerative diseases (as NS-2330)
- Significant unintended weight loss was observed in patients receiving tesofensine during PD/AD trials
- Weight loss was dose-dependent across the studied dose range
- This serendipitous finding led to repositioning tesofensine as an anti-obesity drug
- The weight loss occurred without any dietary intervention or weight loss counseling
- Demonstrated the central appetite-suppressive properties of triple monoamine reuptake inhibition
Study Design
Post-hoc analysis of body weight changes in patients enrolled in Phase 2 trials of tesofensine for Parkinson's disease and Alzheimer's disease. Weight loss was an unexpected secondary observation that prompted the drug's repositioning for obesity treatment.
Limitations
- Secondary/post-hoc analysis, not a prospectively designed weight loss trial
- Population (PD/AD patients) not representative of typical obesity population
- Concurrent medications for neurological conditions may confound results
- Small sample sizes in original neurological trials
Clinical Relevance
This is the "origin story" of tesofensine as an anti-obesity agent. The serendipitous discovery of weight loss in neurological trial participants is a classic example of drug repositioning. The observation that triple monoamine reuptake inhibition produces meaningful weight loss without deliberate caloric restriction underscores the central role of dopamine, norepinephrine, and serotonin in appetite regulation.
Related
#research #observational #tesofensine #evidence-level-III